Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01753765 · ClinicalTrials.gov registry record · NA
Study Evaluating the Treatment of Occipital Neuralgia
A NA study of Occipital Neuralgia, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
- 3
- Study locations
NCT01753765: Completed NA study of Occipital Neuralgia, sponsored by Pacira Pharmaceuticals.
NCT01753765 is a NA study of Occipital Neuralgia that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01753765, a NA study of Occipital Neuralgia, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
- 3
- Study locations
Study Summary
A proof of concept study to evaluate the feasibility of safe and effective treatment through optimization of the Cryo-Touch III device for temporary relief of or reduction in pain due to occipital neuralgia.
Primary Outcome
Improvement of pain due to occipital neuralgia as measured on the Visual Analog Scale (VAS) for pain at Days 7 and 30 as compared to baseline (Day 0). 0= no pain, 10= worst pain imaginable. Higher scores equal worse outcome.
Conditions Studied
Interventions
- DEVICE Device: Cryo-Touch III Study treatment at Day 0.
Study Locations (3)
California
- Neurovations - Napa
Idaho
- Injury Care Medical Center - Boise
Kansas
- International Clinical Research - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-07 |
| Phase | NA |
What the finished NCT01753765 record still lists
NCT01753765 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Occipital Neuralgia appearing as the primary indexed condition, and to 1 intervention - of which Device: Cryo-Touch III Study treatment at Day 0. is the first listed.
NCT01753765 reports a single indexed study location in California, Idaho, Kansas.
Frequently Asked Questions
What is clinical trial NCT01753765 about?
NCT01753765 is a clinical study titled "Study Evaluating the Treatment of Occipital Neuralgia". A proof of concept study to evaluate the feasibility of safe and effective treatment through optimization of the Cryo-Touch III device for temporary relief of or reduction in pain due to occipital neuralgia.
What is the current status of trial NCT01753765?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2012-10. Estimated completion is 2014-07.
What conditions does trial NCT01753765 study?
This clinical trial studies the following conditions: Occipital Neuralgia.
What interventions are being tested in trial NCT01753765?
The interventions under investigation include: Device: Cryo-Touch III Study treatment at Day 0. (DEVICE).
Who is sponsoring clinical trial NCT01753765?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01753765 being conducted?
This trial has 3 study locations across California, Idaho, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Occipital Neuralgia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01753765's enrollment target sits among peer trials
26 1710th of 2000 higher than 289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia